Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Prostatic Neoplasms × Therapeutics × Clear all

Phase

Status

Completed 8 Terminated 3 Withdrawn 1 Unknown 1 Recruiting 1 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 5 Uterine Cervical Neoplasms 2 Thyroid Neoplasms 2 Lung Neoplasms 2 Depression 2 Carcinoma, Non-Small-Cell Lung 2 Urogenital Neoplasms 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Treatment Adherence and Compliance 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Smoking Cessation 1 Sarcoma 1 Pyloric Stenosis, Hypertrophic 1 Prostatic Neoplasms 1 Postoperative Hemorrhage 1 Peripheral Lung Tumor 1 Patient Acceptance of Health Care 1 Pancreatic Ductal Adenocarcinoma (PDAC) 1 Obesity 1 Mycoses 1 Mouth Neoplasms 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Magnetic Resonance Spectroscopy 49 Specimen Handling 38 enzalutamide 32 Radiosurgery 27 Androgen Antagonists 27 Radiotherapy 26 Abiraterone Acetate 23 Pluvicto 21 darolutamide 20 Prednisone 20 Docetaxel 19 apalutamide 17 Leuprolide 16 Standard of Care 15 Radiation 15 gallium 68 PSMA-11 13 Goserelin 13 Blood Specimen Collection 13 Biopsy 13 Triptorelin Pamoate 12 relugolix 11 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11 abiraterone 11 Surveys and Questionnaires 11 pembrolizumab 9 X-Rays 9 Photons 8 Methods 8 Interviews as Topic 8 Educational Status 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05582772 2025-07-03

TOPCOP3

University Health Network, Toronto

Phase NA Recruiting

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡